As with some other ovarian cancer biomarkers, CA125/MUC16 expressing cells signaling enhance epidermal growth factor receptor (EGFR) activation, which results in increasing its downstream effectors Akt and ERK1/2 and in enhanced MMP-2 and MMP-9 expression [26]. This evidence concerns the gene AKT1 and ovarian cancer.